Amit Garg

1.5k total citations · 2 hit papers
39 papers, 1.1k citations indexed

About

Amit Garg is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging and Surgery. According to data from OpenAlex, Amit Garg has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Radiology, Nuclear Medicine and Imaging and 5 papers in Surgery. Recurrent topics in Amit Garg's work include HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (18 papers) and Peptidase Inhibition and Analysis (8 papers). Amit Garg is often cited by papers focused on HER2/EGFR in Cancer Research (18 papers), Monoclonal and Polyclonal Antibodies Research (18 papers) and Peptidase Inhibition and Analysis (8 papers). Amit Garg collaborates with scholars based in United States, United Kingdom and Japan. Amit Garg's co-authors include Joseph P. Balthasar, A Ayyagarí, Bert L. Lum, Hanbin Li, Pierfrancesco Tassone, Paulo M. Hoff, Jorge Barriuso, Ron Yu, Daisuke Wada and Manish A. Shah and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Amit Garg

38 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials

2024 71 citations Alexa B. Kimball, Gregor B. E. Jemec et al. profile →
Hidradenitis suppurativa

2025 21 citations Amit Garg et al. profile →

Peers

Countries citing papers authored by Amit Garg

Since Specialization

Citations

This map shows the geographic impact of Amit Garg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amit Garg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amit Garg more than expected).

Fields of papers citing papers by Amit Garg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amit Garg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amit Garg. The network helps show where Amit Garg may publish in the future.

Co-authorship network of co-authors of Amit Garg

This figure shows the co-authorship network connecting the top 25 collaborators of Amit Garg. A scholar is included among the top collaborators of Amit Garg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amit Garg. Amit Garg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension 2025 ·Journal of the American Academy of Dermatology ·Christopher J. Sayed, (unknown), Amit Garg, Haley B. Naik, Alexa B. Kimball, Christos C. Zouboulis, Gregor B. E. Jemec, Georgios Kokolakis, John R Ingram, Akimichi Morita, (unknown), (unknown), Robert Rolleri, (unknown), Jérémy Lambert, (unknown), Falk G. Bechara	0
2	Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to <6 and 6–11 years 2024 ·British Journal of Clinical Pharmacology ·(unknown), Zufei Zhang, Anthony Lee, Keenan Fenton, (unknown), Amit Garg, Yen Lin Chia	2
3	Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma 2024 ·Clinical Cancer Research ·Zufei Zhang, (unknown), (unknown), Keenan Fenton, (unknown), (unknown), Joy Jiang, Sharon M. Castellino, Kara M. Kelly, Peter D. Cole, Frank G. Keller, Amit Garg, Yen Lin Chia	2
4	Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma 2024 ·Clinical Pharmacology & Therapeutics ·Peiying Zuo, Peter L. Bonate, Amit Garg, Maria Matsangou, Mei Tang	4
5	Physiologically based pharmacokinetic model to predict drug–drug interactions with the antibody–drug conjugate enfortumab vedotin 2023 ·Journal of Pharmacokinetics and Pharmacodynamics ·Mary Choules, Peiying Zuo, (unknown), Amit Garg, Mei Tang, Peter L. Bonate	11
6	Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer 2019 ·Anti-Cancer Drugs ·Yang Luo, Wěi Li, Zefei Jiang, Qingyuan Zhang, Liwei Wang, Yixiang Mao, Vivianne C. G. Tjan‐Heijnen, Seock‐Ah Im, Robin McConnell, (unknown), Debora Fumagalli, José Bines, Bei Wang, Amit Garg, Whitney P. Kirschbrown, Binghe Xu	3
7	Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study 2019 ·Cancer Chemotherapy and Pharmacology ·Whitney P. Kirschbrown, Matts Kågedal, Bei Wang, Lars Lindbom, Adam Knott, (unknown), Sharareh Monemi, Ihsan Nijem, Sandhya Girish, (unknown), Debora Fumagalli, Robin McConnell, Guy Jérusalem, Chris Twelves, José Baselga, Gϋnter von Minckwitz, José Bines, Amit Garg	9
8	Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer 2019 ·Journal for ImmunoTherapy of Cancer ·Colby S. Shemesh, Pascal Chanu, Kris M. Jamsen, (unknown), Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, René Bruno, Jin Jin, Sandhya Girish	36
9	Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer 2019 ·Cancer Chemotherapy and Pharmacology ·Whitney P. Kirschbrown, Bei Wang, Ihsan Nijem, Atsushi Ohtsu, Paulo M. Hoff, Manish A. Shah, Lin Shen, Yoon‐Koo Kang, María Alsina, Sandhya Girish, Amit Garg	9
10	Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors 2018 ·Cancer Chemotherapy and Pharmacology ·Angelica Quartino, Hanbin Li, Whitney P. Kirschbrown, (unknown), Daisuke Wada, Amit Garg, Jin Y. Jin, Bert L. Lum	27
11	Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study 2018 ·The Journal of Clinical Pharmacology ·Whitney P. Kirschbrown, Chris Wynne, Matts Kågedal, (unknown), Hanbin Li, Bei Wang, Ihsan Nijem, Tanja Badovinac Črnjević, (unknown), Sarah Heeson, Jennifer Eng‐Wong, Amit Garg	28
12	Bariatric surgery in old age: a comparative study of laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy in an Asia centre of excellence 2015 ·Journal of Biomedical Research ·(unknown), Amit Garg, (unknown), (unknown), (unknown)	20
13	A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer 2014 ·British Journal of Cancer ·(unknown), Sun Young Rha, Pierfrancesco Tassone, Jorge Barriuso, Ron Yu, Tania Szado, Amit Garg, (unknown)	75
14	Could clomiphene kindle acute manic episode in a male patient? A case report 2014 ·General Hospital Psychiatry ·(unknown), Amit Garg	3
15	Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors 2014 ·Cancer Chemotherapy and Pharmacology ·Amit Garg, Angelica Quartino, Jing Li, Jin Jin, Daisuke Wada, Hanbin Li, Javier Cortés, Virginia McNally, Graham Ross, Jennifer Visich, Bert L. Lum	49
16	Pertuzumab Pharmacokinetics and Safety in Combination with Trastuzumab and Chemotherapy in Patients with Her2-Positive Advanced Gastric Cancer (Agc) 2013 ·Annals of Oncology ·Yoon‐Koo Kang, Sun Young Rha, Pierfrancesco Tassone, Jorge Barriuso, Ron Yu, Tania Szado, Amit Garg, Yung‐Jue Bang	6
17	Absence of pharmacokinetic drug–drug interaction of pertuzumab with trastuzumab and docetaxel 2013 ·Anti-Cancer Drugs ·Javier Cortés, Sandra M. Swain, Iveta Kudaba, Maik Hauschild, Taral Patel, (unknown), Norikazu Masuda, Virginia McNally, Graham Ross, Mike Brewster, Jean‐Francois Marier, (unknown), Amit Garg, Ihsan Nijem, Jennifer Visich, Bert L. Lum, José Baselga	19
18	黒皮症:包括的最新情報:パートII 2011 ·Journal of the American Academy of Dermatology ·(unknown), Amit Garg	65
19	Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects 2011 ·Biopharmaceutics & Drug Disposition ·Rajesh Krishna, Daria Stypinski, (unknown), Amit Garg, Isaias Noel Gendrano, Andrea Maes, (unknown), Yang Liu, (unknown), (unknown), John A. Wagner, S. Aubrey Stoch	11
20	Nucleotide Polymorphism Associated with Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis 2006 ·Current Microbiology ·Shashikant Srivastava, Amit Garg, A Ayyagarí, Kishan Kumar Nyati, Tapan N. Dhole, S.K. Dwivedi	33

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact